Remarkably, CD43 deficiency did not affect the percentage of NKG2A+CD8+ T cells in the blood but rather resulted in a diminution of NKG2A+CD8+ T cells in the TME (Figure 7H), indicating that tumor migration of therapy-responsive T cells is regulated by CD43, which is in line with the ability of the CD431B11 isoform to function as a ligand for the cell adhesion molecule E-selectin (CD62E).52 This evidence concerns the gene KLRC1 and neoplasm.